治疗METex14跳跃突变非小细胞肺癌新药——谷美替尼OA

The MET exon 14(METex14)skipping mutation is an important therapeutic target in non-small cell lung cancer(NSCLC).Glumetinib,a highly selective oral MET inhibitor developed in China,has gained approval in China and Japan for treating lo-cally advanced or metastatic NSCLC harboring the METex14 skipping mutation.Preclinically,glume-tinib selectively inhibits c-Met kinase activity and its downstream signaling pathways,demonstrating an inhibition rate exceeding 87.7%against MET-driven tumors.In a pivotal phase II study involving 79 pa-tients with METex14-positive NSCLC,glumetinib treatment yielded an objective response rate(ORR)of 66%and a median progression-free survival(PFS)of 8.5 months.The incidence of grade≥3 treat-ment-related adverse events(TRAEs)was 54%,pri-marily edema,hypoalbuminemia,and transami-nase elevations.Treatment discontinuation due to adverse events occurred in only 8%of patients,in-dicating a manageable safety profile.Glumetinib thus represents a novel and effective therapeutic option for NSCLC patients with METex14 skipping mutations,particularly in managing brain metas-tases.Its clinical application is expanding to include overcoming drug resistance and exploring combina-tion therapies.This paper aims to concisely review Glumetinib's structural properties,pharmacokinet-ics,efficacy,safety profile,drug interactions,and potential in combination therapy.Furthermore,it seeks to outline future applications of this drug,providing a valuable reference for clinical medica-tion selection in NSCLC management.